Skip to content
Clinical Trials – home

Hospital Son Llatzer

Verified siteinfo

Spain Carretera De Manacor Km 4, 07198 Palma, Spain

  • 37 trials recruiting
  • Non-small cell lung cancer · Plasma cell myeloma · Hypertrophic cardiomyopathy
  • Adult patients

About Specializations

Hospital Son Llatzer in Palma, Spain specialises in clinical trials of conditions such as Non-small cell lung cancer, Plasma cell myeloma, Hypertrophic cardiomyopathy, Non-small cell lung cancer stage IV, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases and Inherited Heart Conditions

At Hospital Son Llatzer in Palma, clinical research in cardiology focuses on cardiovascular disease and congenital, hereditary, and neonatal disorders, with particular attention to people at risk of developing dilated cardiomyopathy. The studies are designed to explore whether earlier treatment can help protect heart function and reduce the chance of structural changes before symptoms appear.

  • Genetic carriers of dilated cardiomyopathy-causing variants
  • Preventing decline in heart pumping function and ventricular enlargement
  • Evaluating early therapy to delay or reduce disease expression

These trials aim to improve prevention and long-term monitoring for individuals with inherited heart risk.

Hypertrophic Cardiomyopathy and Exercise Capacity

Research at this site also examines symptomatic obstructive hypertrophic cardiomyopathy, a condition that can limit daily activity and cause significant heart-related symptoms. The clinical trials are comparing treatment options to better understand how to improve exercise tolerance and overall symptom control in affected adults.

  • Symptomatic obstructive hypertrophic cardiomyopathy
  • Improving exercise capacity and symptom management
  • Comparing a newer heart therapy with standard treatment

The goal is to find approaches that may offer better functional outcomes for people living with this form of cardiomyopathy.

Neoplasms and Lung Cancer

Clinical trial activity at Hospital Son Llatzer includes research in neoplasms, especially metastatic non-small cell lung cancer. These studies are testing whether new treatment combinations can improve outcomes for patients whose disease has spread and whose tumors show low PD-L1 expression.

  • Metastatic non-small cell lung cancer
  • Assessing treatment effectiveness in advanced cancer
  • Exploring whether new combinations can extend survival and delay progression

This work supports the search for more effective options in advanced lung cancer care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Carretera De Manacor Km 407198 PalmaSpain
Recruiting now
37 trials
Conditions studied
78
Partner status
Verified site

More sites in PalmaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

97 clinical trials

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Long‑Term Safety and Efficacy Study of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danicamtiv
  • Sponsor:Kardigan Inc.

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:AnaCardio AB

Long‑Term Study of Acoramidis on Heart Function and Amyloid Burden in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR‑CM)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis
  • Sponsor:Eidos Therapeutics Inc.

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Polyneuropathy

Recruiting

A study to evaluate the safety and effectiveness of nucresiran and vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nucresiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Coramitug
  • Sponsor:Novo Nordisk A/S

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Haemato Oncology Foundation For Adults Netherlands

A Study of Danicamtiv for Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy to Test if it Improves Heart Function and Exercise Ability

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danicamtiv
  • Sponsor:Kardigan Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.